Kezar Life Sciences Statistics
Share Statistics
Kezar Life Sciences has 7.31M
shares outstanding. The number of shares has increased by -89.96%
in one year.
| Shares Outstanding | 7.31M |
| Shares Change (YoY) | -89.96% |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | 5.73% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 827 |
| FTD / Avg. Volume | 2.9% |
Short Selling Information
The latest short interest is 68.13K, so 0.93% of the outstanding
shares have been sold short.
| Short Interest | 68.13K |
| Short % of Shares Out | 0.93% |
| Short % of Float | 0.95% |
| Short Ratio (days to cover) | 2.4 |
Valuation Ratios
The PE ratio is -5.85 and the forward
PE ratio is -0.55.
Kezar Life Sciences's PEG ratio is
0.33.
| PE Ratio | -5.85 |
| Forward PE | -0.55 |
| PS Ratio | 0 |
| Forward PS | 2.3 |
| PB Ratio | 4.19 |
| P/FCF Ratio | -6.6 |
| PEG Ratio | 0.33 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Kezar Life Sciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.76,
with a Debt / Equity ratio of 0.14.
| Current Ratio | 6.76 |
| Quick Ratio | 6.76 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.22 |
| Interest Coverage | 56.88 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,522,472.73 |
| Employee Count | 55 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -94.96% in the
last 52 weeks. The beta is 0.6, so Kezar Life Sciences's
price volatility has been higher than the market average.
| Beta | 0.6 |
| 52-Week Price Change | -94.96% |
| 50-Day Moving Average | 4.94 |
| 200-Day Moving Average | 19.52 |
| Relative Strength Index (RSI) | 39.35 |
| Average Volume (20 Days) | 28,498 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -90.61M |
| Net Income | -83.74M |
| EBITDA | -90.61M |
| EBIT | -85.33M |
| Earnings Per Share (EPS) | -1.15 |
Full Income StatementBalance Sheet
The company has 41.75M in cash and 16.18M in
debt, giving a net cash position of 25.57M.
| Cash & Cash Equivalents | 41.75M |
| Total Debt | 16.18M |
| Net Cash | 25.57M |
| Retained Earnings | -434.5M |
| Total Assets | 144.68M |
| Working Capital | 117.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -74.21M
and capital expenditures -29K, giving a free cash flow of -74.24M.
| Operating Cash Flow | -74.21M |
| Capital Expenditures | -29K |
| Free Cash Flow | -74.24M |
| FCF Per Share | -1.02 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
